{"success":true,"data":{"pressRelease":{"id":"77117","rtpr_id":"nGNXbKKGGz","ticker":"ZEAL","exchange":"NASDAQ","all_tickers":["ZEAL","ZELA"],"title":"Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.","author":"Globe Newswire","published_at":"2026-06-30T20:00:00.293Z","article_body":"Company announcement No. 29 / 2026\n\nZealand Pharma major shareholder announcement: The Capital Group Companies,\nInc.\n\nCopenhagen, Denmark, June 30, 2026 – Zealand Pharma A/S (\"the Company\" or\n“Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology\ncompany transforming the future of metabolic health, today reports receipt on\n30 June 2026 of notification pursuant to Section 38 of the Danish Capital\nMarkets Act from the following major shareholder:\n\nAs of 26 June 2026, The Capital Group Companies, Inc. held voting rights\ncorresponding to 4.79% of the total voting rights in Zealand Pharma A/S. The\nCapital Group Companies notes that neither The Capital Group Companies nor any\nof its affiliates own shares of Zealand Pharma A/S for its own account.\nRather, the shares reported in this major shareholder notification are owned\nby accounts under the discretionary investment management of one or more of\nthe investment management companies described in the notification form\nattached.\n\nPlease see further details in the attached notification form.\n\nAbout Zealand Pharma\nZealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on\nadvancing medicines for obesity and metabolic health. Combining more than 25\nyears of peptide R&D expertise with a proprietary data platform that leverages\nadvanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new\nera in obesity and metabolic health. To date, more than 10 Zealand Pharma\ninvented drug candidates have entered clinical development, of which two\nproducts have reached the market and three candidates are in late-stage\ndevelopment. The Company has collaborations with global pharmaceutical and\nbiotechnology partners for research, development, and commercialization.\nFounded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with\na U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.\n\nContacts\nEric Rojas (Investors)\nVice President, Head of Investor Relations\nZealand Pharma\nEmail: erojas@zealandpharma.com\n\nNeshat Anis Ahmadi (Investors)\nInvestor Relations Manager\nZealand Pharma\nEmail: neahmadi@zealandpharma.com\n\nRachel James-Owens (Media)\nVice President, Corporate Communications and Media Relations\nZealand Pharma\nEmail: rjamesowens@zealandpharma.com\n\nAndreas Hylleberg Mølleskov (Media) \nDirector, External Communications\nZealand Pharma\nEmail: ahylleberg@zealandpharma.com\n\nAttachment\n*     Zealand_Pharma_AS_6.26.2026\n(https://ml-eu.globenewswire.com/Resource/Download/f5e76fc2-b4ce-47ee-95fb-a38b71a7b316)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/31b5d115-c4a3-4dfd-b20e-d222199c4862)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbKKGGz","title":"Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.","author":"Globe Newswire","ticker":"ZEAL","created":"2026-06-30T20:00:00.293Z","tickers":["ZEAL","ZELA"],"exchange":"NASDAQ","article_body":"Company announcement No. 29 / 2026\n\nZealand Pharma major shareholder announcement: The Capital Group Companies,\nInc.\n\nCopenhagen, Denmark, June 30, 2026 – Zealand Pharma A/S (\"the Company\" or\n“Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology\ncompany transforming the future of metabolic health, today reports receipt on\n30 June 2026 of notification pursuant to Section 38 of the Danish Capital\nMarkets Act from the following major shareholder:\n\nAs of 26 June 2026, The Capital Group Companies, Inc. held voting rights\ncorresponding to 4.79% of the total voting rights in Zealand Pharma A/S. The\nCapital Group Companies notes that neither The Capital Group Companies nor any\nof its affiliates own shares of Zealand Pharma A/S for its own account.\nRather, the shares reported in this major shareholder notification are owned\nby accounts under the discretionary investment management of one or more of\nthe investment management companies described in the notification form\nattached.\n\nPlease see further details in the attached notification form.\n\nAbout Zealand Pharma\nZealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on\nadvancing medicines for obesity and metabolic health. Combining more than 25\nyears of peptide R&D expertise with a proprietary data platform that leverages\nadvanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new\nera in obesity and metabolic health. To date, more than 10 Zealand Pharma\ninvented drug candidates have entered clinical development, of which two\nproducts have reached the market and three candidates are in late-stage\ndevelopment. The Company has collaborations with global pharmaceutical and\nbiotechnology partners for research, development, and commercialization.\nFounded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with\na U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.\n\nContacts\nEric Rojas (Investors)\nVice President, Head of Investor Relations\nZealand Pharma\nEmail: erojas@zealandpharma.com\n\nNeshat Anis Ahmadi (Investors)\nInvestor Relations Manager\nZealand Pharma\nEmail: neahmadi@zealandpharma.com\n\nRachel James-Owens (Media)\nVice President, Corporate Communications and Media Relations\nZealand Pharma\nEmail: rjamesowens@zealandpharma.com\n\nAndreas Hylleberg Mølleskov (Media) \nDirector, External Communications\nZealand Pharma\nEmail: ahylleberg@zealandpharma.com\n\nAttachment\n*     Zealand_Pharma_AS_6.26.2026\n(https://ml-eu.globenewswire.com/Resource/Download/f5e76fc2-b4ce-47ee-95fb-a38b71a7b316)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/31b5d115-c4a3-4dfd-b20e-d222199c4862)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-30T20:00:00.32583771Z","server_sent_at_ms":1782849600325},"received_at":"2026-06-30T20:00:00.378Z","source_url":null},"analysis":{"id":"66362","press_release_id":"77117","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Zealand Pharma A/S disclosed that The Capital Group Companies, Inc. held voting rights corresponding to 4.79% of the total share capital as of June 26, 2026.\n\nThe notification, made pursuant to Section 38 of the Danish Capital Markets Act, specifies that the shares are held under discretionary investment management accounts rather than for Capital Group's own account.\n\nZealand Pharma is a biotechnology company focused on metabolic health, with multiple drug candidates currently in clinical development.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine ownership disclosure"},"keyFigures":{"customDimensions":{"voting_rights_percent":"4.79%"}},"quotedText":"","namedEntities":{"people":[{"name":"Eric Rojas","role":"Vice President, Head of Investor Relations"},{"name":"Neshat Anis Ahmadi","role":"Investor Relations Manager"},{"name":"Rachel James-Owens","role":"Vice President, Corporate Communications and Media Relations"},{"name":"Andreas Hylleberg Mølleskov","role":"Director, External Communications"}],"products":[],"companies":[{"name":"The Capital Group Companies, Inc.","relationship":"major shareholder"},{"name":"Zealand Pharma A/S","ticker":"ZEAL"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine statutory notification regarding a major shareholder's voting rights percentage. No action by the company, financial results, or operational updates were disclosed."},"tickerRelevance":{"others":[],"primary":"ZEAL"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small_cap","eventGravity":"ownership_filing"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Zealand Pharma A/S disclosed that The Capital Group Companies, Inc. held voting rights corresponding to 4.79% of the total share capital as of June 26, 2026.\n\nThe notification, made pursuant to Section 38 of the Danish Capital Markets Act, specifies that the shares are held under discretionary investment management accounts rather than for Capital Group's own account.\n\nZealand Pharma is a biotechnology company focused on metabolic health, with multiple drug candidates currently in clinical development.","key_figures":{"customDimensions":{"voting_rights_percent":"4.79%"}},"named_entities":{"people":[{"name":"Eric Rojas","role":"Vice President, Head of Investor Relations"},{"name":"Neshat Anis Ahmadi","role":"Investor Relations Manager"},{"name":"Rachel James-Owens","role":"Vice President, Corporate Communications and Media Relations"},{"name":"Andreas Hylleberg Mølleskov","role":"Director, External Communications"}],"products":[],"companies":[{"name":"The Capital Group Companies, Inc.","relationship":"major shareholder"},{"name":"Zealand Pharma A/S","ticker":"ZEAL"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-30T20:01:39.968Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small_cap","eventGravity":"ownership_filing"}},"durationMs":99581,"modelName":"george-droid-qwen-72b"}}